Table 1.

Baseline Characteristics of the Study Patients in the FAST-1 and FAST-2 Trials, According to Study Group.^*

Characteristic	FAST-1		FAST-2
	Icatibant (N = 27)	Placebo (N = 29)	Icatibant (N = 36)	Tranexamic Acid (N = 38)
Sex — no. (%)
Male	11 (41)	8 (28)	12 (33)	15 (39)
Female	16 (59)	21 (72)	24 (67)	23 (61)
Age — yr	34.8±9.8	34.9±11.4	40.4±13.6	41.9±12.4
Weight — kg	80.3±21.1	76.0±21.9	80.1±16.1	74.2±15.6
Type of HAE attack — no.
Cutaneous	14	13	24	23
Abdominal	13	16	12	15
No. of attacks in previous 6 mo — median (range)
Cutaneous	6 (1–44)	6 (1–50)	6 (1–24)	5 (1–25)
Abdominal	3 (1–24)	5 (2–16)	3 (1–15)	3 (1–72)
Cutaneous and abdominal	2 (1–40)	5 (1–12)	4 (1–24)	2 (1–12)
Laryngeal	1 (1–4)	1 (1–9)	2 (1–7)	1 (1–6)

^*Plus–minus values are means ±SD. HAE denotes hereditary angioedema.